Teresa Sadras

The paper introduces a probe-based workflow to detect oncogenic gene fusions in single-cell RNA-seq, validated in cancer cell lines and pediatric B-ALL cohorts.

This paper introduces CRISPR-PspCas13b as a method to systematically silence oncogenic fusion transcripts, showing effectiveness against drug-resistant cancer drivers.

TALLSorts classifies T-ALL samples using bulk RNA-seq data with high accuracy across four international cohorts.

This paper develops CRISPR-Cas13 crRNAs that selectively silence oncogenic SNV transcripts with single-base precision by exploiting mismatch intolerance in target-spacer interactions.

This study designs CRISPR-Cas13b crRNAs with single-base precision to silence oncogenic gene fusions, enhancing targeting efficacy and selectivity.

JAFFAL detects fusion genes from long-read transcriptome sequencing with high accuracy, outperforming existing methods and enabling single-cell resolution.